Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 23Sarcoma 18Neoplasms 8Neoplasm Metastasis 8Breast Neoplasms 8Ovarian Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Fallopian Tube Neoplasms 6Liposarcoma 5Leiomyosarcoma 5Hemangiosarcoma 5Sarcoma, Synovial 4Neurofibrosarcoma 4Lung Neoplasms 4Kidney Neoplasms 4Histiocytoma, Malignant Fibrous 4Urinary Bladder Neoplasms 3Recurrence 3Prostatic Neoplasms 3Glioblastoma 3Thyroid Carcinoma, Anaplastic 2Small Cell Lung Carcinoma 2Sarcoma, Alveolar Soft Part 2Pancreatic Neoplasms 2Neuroendocrine Tumors 2Melanoma 2Gliosarcoma 2Fibrosarcoma 2Dermatofibrosarcoma 2Clear-cell metastatic renal cell carcinoma 2

Interventions

Sunitinib 16Imatinib Mesylate 13nilotinib 8ripretinib 4regorafenib 4avapritinib 34-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 3pexidartinib 2pembrolizumab 2Bevacizumab 2trametinib 1tinostamustine 1spartalizumab 1romidepsin 1ponatinib 1pazopanib 1palbociclib 1olaratumab 1guadecitabine 1ferric carboxymaltose 1epacadostat 1dabrafenib 1cediranib 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Sorafenib 1STA 9090 1Observation 1Iron-Dextran Complex 1Indocyanine Green 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Gastrointestinal Stromal Tumors × pazopanib × Clear all
NCT01391611 2017-04-07

Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)

Stanford University

Phase 2 Terminated
25 enrolled 7 charts
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡